Text Size

Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hiroyuki Marusawa, Kyoto University
ClinicalTrials.gov Identifier:
NCT00375661
First received: September 12, 2006
Last updated: April 5, 2012
Last verified: April 2012
History of Changes
  Purpose

The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.


Condition Intervention Phase
Hepatitis C, Chronic
 Drug: interferon-alfa-2b and ribavirin
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Kyoto University:

Primary Outcome Measures:
  • Incidence of adverse effect of interferon [ Time Frame: During the treatment period ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: September 2006
Estimated Study Completion Date: February 2013
Estimated Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: interferon Drug: interferon-alfa-2b and ribavirin
Interferon, pnce per week plus daily ribavirin

  Eligibility

Ages Eligible for Study:   25 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of Hepatocellular carcinoma due to Chronic Hepatitis C Virus Infection.
  • Must be treated with curative treatment for primary tumor using either surgical resection or radiofrequency ablation therapy

Exclusion Criteria:

  • No recurrence of hepatocellular carcinoma 3 months after the primary treatment
  • Renal dysfunction
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00375661

Locations
Japan
Department of Gastroenterology and Hepatology, Kyoto University Hospital
Kyoto, Japan
Osaka Red Cross Hospital
Osaka, Japan
Sponsors and Collaborators
Kyoto University
Investigators
Study Chair: Tsutomu Chiba, M.D.,Ph.D. Kyoto University
  More Information

No publications provided

Responsible Party: Hiroyuki Marusawa, Associate professor, Kyoto University
ClinicalTrials.gov Identifier: NCT00375661     History of Changes
Other Study ID Numbers: O2006-415
Study First Received: September 12, 2006
Last Updated: April 5, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Kyoto University:
hepatocellular carcinoma

Additional relevant MeSH terms:
Carcinoma
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
 RNA Virus Infections
Flaviviridae Infections
Hepatitis, Chronic
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Interferon-alpha
Interferon Alfa-2a
Interferon Alfa-2b
Interferons
Ribavirin
Reaferon
Antiviral Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on May 23, 2013